Article Access statistics

Viewed: 659

Emailed: 0

PDF Downloaded: 286

Indian Journal of Pharmacy and Pharmacology


A single-dose, open-label, two-treatment, two-period, two-sequence, two-way cross-over bioavailability & bioequivalence study to compare two formulation of Olmesartan 40 mg in healthy adults in fed state


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Mohit Changani*, Ameet Soni, Ambrish Singh, Harsh Choksi, Lokesh Kumar

Volume : 6, Issue : 4, Year : 2019

Article Page : 121-125


Suggest article by email


Abstract

Introduction: Olmesartan medoxomil is an ester prodrug commonly prescribed to treat high blood pressure, heart failure, and diabetic kidney disease.
Aim: To study the bioequivalence of Olvas tablets (containing olmesartan medoxomil 40mg) of Cadila Pharmaceuticals Ltd., India with Benicar® tablets (containing olmesartan medoxomil 40mg) of Daiichi Sankyo, Inc., Parsippany, New Jersey.
Materials and Methods: Forty healthy, adult, male subjects were studied in a single-dose, open-label, two-treatment, two-period, two-sequence, two-way cross-over study. Detailed demographic data along with clinical examination, vital signs, medical history, laboratory tests including hematology, biochemistry, serology and urine analysis. ECG and chest X-ray were performed. Pharmacokinetic primary parameters like Cmax, AUC0-t, AUC0-? and secondary parameters like Tmax, t1/2, Kel, and AUC Extrapolation were calculated for both the drug formulations.
Results: Demographic parameters were comparable for both the treatment arms. Olmesartan medoxomil 40mg of Cadila Pharmaceuticals Ltd was found to in the acceptance range for bioequivalence, 80.00-125.00% for the 90% confidence intervals for the difference of means of Ln-transformed parameters Cmax, AUC0-t and AUC0-?.
Conclusion: Both Olmesartan Medoxomil tablets 40mg (containing olmesartan medoxomil 40mg) of Cadila Pharmaceuticals Ltd., India with Benicar® tablets 40mg (containing olmesartan medoxomil 40mg) of Daiichi Sankyo, Inc., Parsippany, New Jersey were found to be bioequivalent.

Keywords: Olmesartan, Bioavailability, Bioequivalence, Pharmacokinetics.


Doi : 10.18231/j.ijpp.2019.026

How to cite : Changani M, Soni A, Singh A, Choksi H, Kumar L, A single-dose, open-label, two-treatment, two-period, two-sequence, two-way cross-over bioavailability & bioequivalence study to compare two formulation of Olmesartan 40 mg in healthy adults in fed state. Indian J Pharm Pharmacol 2019;6(4):121-125

Copyright © 2019 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)